Biogen: Amyotrophic Lateral Sclerosis trials

The registry lists 10 Amyotrophic Lateral Sclerosis studies with Biogen as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 5Phase 2 3Phase 3 1Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT07855211Phase 1/2
• A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT07259980
• MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT04579666Phase 2Results posted
• A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic MutationTerminatedNCT04494256Phase 1/2Results posted
• An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02623699Phase 3Results posted
• A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)Active, not recruitingNCT07223723Phase 4
• Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT04288856Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral SclerosisCompletedNCT03945279Phase 1
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral SclerosisCompletedNCT03626012Phase 1
• Methodology Study of Novel Outcome Measures to Assess Progression of ALSCompletedNCT02611674